Quarterly report pursuant to Section 13 or 15(d)

Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details)

v3.24.3
Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Expenses) (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Accounts Payable and Accrued Expenses    
Accounts payable $ 8,759 $ 6,322
Accrued research and development 561 4,118
Accrued compensation 984 2,838
Other 1,757 739
Total accounts payable and accrued expenses 12,061 $ 14,017
Accrued consideration for the uBriGene Asset Purchase Agreement $ 1,300